Journal article
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
F Schettini, N Sobhani, A Ianza, T Triulzi, A Molteni, MC Lazzari, C Strina, M Milani, SP Corona, M Sirico, O Bernocchi, F Giudici, MR Cappelletti, E Ciruelos, G Jerusalem, S Loi, SB Fox, D Generali
Breast Cancer Research and Treatment | SPRINGER | Published : 2020
Open access
Abstract
Purpose: mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the association between treatment-associated immune system features and everolimus activity. Methods: We retrospectively explored a correlation with the therapeutic activity of everolimus and tumor-associated immune pathways with ingenuity pathway analysis (IPA), neutrophil-to-lymphocyte ratio (NLR), circulating lymphocytes, and endothelial cells (CECs) in 3 different HR+ mBC studies, including the BALLET phase IIIb study. Results: The circulating ..
View full abstractGrants
Funding Acknowledgements
Open access funding provided by Universita degli Studi di Trieste within the CRUI-CARE Agreement.